- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03406585
Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes
A Double-blinded, Randomized, Placebo-controlled Trial With Wharton's Jelly Derived Allogeneic Mesenchymal Stromal Cells (WJMSCs) for Preserving Endogenous Insulin Production in Adult Patients Diagnosed for Type 1 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a combined phase I and phase II study, where the first part is an open, dose escalating study consisting of 9 male patients, 18-40 years of age. The second part is a randomized, double-blinded, placebo-controlled, phase I/II study in parallel design comparing allogeneic WJMSC treatment to placebo in adult patients diagnosed with type 1 diabetes. Besides safety, preservation of endogenous insulin production (measured as C-peptide concentrations) together with metabolic control, diabetes treatment satisfaction and immunological profile will be assessed.
A total number of 24 patients will be enrolled in the study and followed for one year after WJMSC/placebo treatment. Patients 18-40 years of age, both male and female, diagnosed for type 1 diabetes will be eligible. Providing informed consent and fulfillment of inclusion criteria and no exclusion criteria, they will within two years of diagnosis be randomized.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 141 86
- Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent for participation of the study, given before undergoing any study-specific procedures
- Clinical history compatible with type 1 diabetes diagnosed less than 2 years before enrolment
- In the first part of the study patients 1-9 only male patients between 18-40 years of age will be included. In the second part of the study, patients 10-24, both male and female patients 18 to 40 years of age (inclusive at both ends) will be included.
- Mentally stable and, in the opinion of the investigator, able to comply with the procedures of the study protocol
- Fasting plasma C-peptide concentration >0.12 nmol/L.
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, if they are using effective methods of contraception during the study. Acceptable birth control methods are those with a failure rate of less than 1% per year when used consistently and correctly. Such methods include (in "Recommendations related to contraception and pregnancy testing in clinical trials", supplied from www.hma.eu/):
Combined (estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation.
- oral
- intravaginal
- transdermal
progestogen-only hormonal contracption associated with inhibition of ovulation
- oral
- injectable
- implantable
- intrauterine device (IUD)
- intrauterine hormone-releasing system (IUS)
- bilateral tubal occlusion
- total abstinence or vasectomized partner.
Exclusion Criteria:
- Inability to provide informed consent
- Patients with body mass index (BMI) > 30, or weight >100 kg
- Patients with weight <50 kg
- Patients with unstable cardiovascular status incl. NYHA class III/IV or symptoms of angina pectoris.
- Patients with uncontrolled hypertension (≥160/105 mmHg).
- Patients with active on-going infections.
- Patients with latent or previous as well as on-going therapy against tuberculosis, or exposed to tuberculosis or has travelled in areas with high risk of tuberculosis or mycosis within the last 3 months.
- Patients with serological evidence of infection with HIV, Treponema pallidum, hepatitis B antigen (patients with serology consistent with previous vaccination and a history of vaccination are acceptable) or hepatitis C.
- Patients with any immune suppressive treatment
- Patients with known demyelinating disease or with symptoms or physical examination findings consistent with possible demyelinating disease-
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
- Patients with known, or previous, malignancy.
- Taking oral anti-diabetic therapies or any other concomitant medication which may interfere with glucose regulation other than insulin.
- Patients with GFR <80 ml/min/1.73 m2 body surface.
- Patients with proliferative retinopathy.
- Patient with any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo treatment with MSC.
- Known hypersensitivity against any excipients, i.e. dimethyl sulfoxide (DMSO).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Allogeneic transplantation with WJMSCs
Single infusion of 200 million cells per patient.
|
The drug is a cell suspension with allogeneic mesenchymal stromal cells derived from umbilical cord tissue.
Other Names:
|
Placebo Comparator: Sham transplantation (placebo)
Single infusion with albumin and dmso in sodium chloride (identical concentrations as active treatment)
|
Placebo treatment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety; measured through set safety parameters
Time Frame: throughout the study untill day 372
|
measured through the registration of adverse events and other safety parameters such as hypoglycemia, allergic reactions, ophthalmologic examination, ECG, vital signs and laboratory assessments.
|
throughout the study untill day 372
|
Efficacy; comparison of the intervention versus placebo at day 372 versus start of treatment
Time Frame: Day 372
|
Delta-change of C-peptide Area Under the Curve (AUC) (0-120 min) for Mixed Meal Tolerance Test (MMTT) at day 372 following WJMSC/Placebo infusion when compared to test performed before start of treatment.
|
Day 372
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients insulin independent (ADA criteria) at days 187 and 372
Time Frame: Days 187 and 372 following WJMSC/Placebo infusion
|
Insulin doses and measured plasma glucose values are written down in the subject's diary every day by the subject.
Amount of insulin, recorded plasma glucose values, time and date will be included
|
Days 187 and 372 following WJMSC/Placebo infusion
|
Number of patients with daily insulin needs <0.25U/kg at days 187 and 372
Time Frame: Days 187 and 372 following WJMSC/Placebo infusion
|
Insulin doses and measured plasma glucose values are written down in the subject's diary every day by the subject.
Amount of insulin, recorded plasma glucose values, time and date will be included
|
Days 187 and 372 following WJMSC/Placebo infusion
|
Insulin requirement/kg BW at days 187 and 372
Time Frame: Days 187 and 372 following WJMSC/Placebo infusion
|
Insulin doses and measured plasma glucose values are written down in the subject's diary every day by the subject.
Amount of insulin, recorded plasma glucose values, time and date will be included
|
Days 187 and 372 following WJMSC/Placebo infusion
|
HbA1c at days 187 and 372.
Time Frame: Days 187 and 372 following WJMSC/Placebo infusion
|
Measurements of HbA1c will be performed to assess metabolic control during study.
|
Days 187 and 372 following WJMSC/Placebo infusion
|
Glucose variability at day 372
Time Frame: Day 372 following WJMSC/Placebo infusion
|
Measurements of HbA1c will be performed to assess metabolic control during study.
|
Day 372 following WJMSC/Placebo infusion
|
Delta change of levels of fasting C-peptide at day 372
Time Frame: Day 372 following WJMSC/Placebo infusion
|
Measured at day 372 compared to before start of treatment
|
Day 372 following WJMSC/Placebo infusion
|
Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372
Time Frame: Day 372 following WJMSC/Placebo infusion
|
Measured at day 372 compared to before start of treatment
|
Day 372 following WJMSC/Placebo infusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Per-Ola Carlsson, MD, PhD, NextCell Pharma
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ProTrans-T1D
- 2017-002766-50 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type1 Diabetes Mellitus
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedType1 Diabetes MellitusUnited States
-
Massachusetts General HospitalCompletedType1 Diabetes MellitusUnited States
-
Universidad Loyola AndaluciaUnknown
-
Jessa HospitalCompleted
-
Eli Lilly and CompanyCompletedA Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)Type1 Diabetes MellitusUnited States
-
AdociaCompleted
-
Second Xiangya Hospital of Central South UniversityRecruitingType1 Diabetes Mellitus | Autoimmune DiabetesChina
-
Chinese University of Hong KongRecruiting
-
REMD Biotherapeutics, Inc.CompletedType1 Diabetes MellitusUnited States
Clinical Trials on ProTrans: Allogeneic transplantation with WJMSCs
-
NextCell Pharma AbActive, not recruiting
-
McGill University Health Centre/Research Institute...Terminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedAcute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Minimal Residual Disease | Therapy-Related Acute Myeloid Leukemia | Therapy-Related Myelodysplastic... and other conditionsUnited States
-
Wake Forest University Health SciencesCompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Christina L. Kaufman PhDUnited States Department of Defense; U.S. Army Medical Research and Development... and other collaboratorsUnknownUpper Extremity InjuriesUnited States
-
Universitätsklinikum Hamburg-EppendorfCompleted
-
University Hospital, BordeauxActive, not recruitingMyelodysplastic SyndromesFrance
-
Hospital Universitario La PazUniversity of MalagaRecruitingTransplant-Related DisorderSpain
-
Karolinska InstitutetMedical University of Vienna; Oslo University Hospital; Sahlgrenska University... and other collaboratorsTerminatedAcute Myeloid LeukemiaCanada, Austria, Sweden, Russian Federation, Norway
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedHematological MalignanciesUnited States